Category Press Releases

Ailux Biologics Triumphantly UCB Collaborates with XtalPi Division to Revolutionize AI-Powered Biologics

Ailux Biologics UCB\u2019s Strategic Collaboration with Ailux Biologics Ailux Biologics UCB, a leading global biopharmaceutical company, and XtalPi, an industry pioneer in AI-powered drug discovery, have announced a landmark license agreement involving XtalFold™, an advanced biologics AI platform. Developed by…

Read MoreAilux Biologics Triumphantly UCB Collaborates with XtalPi Division to Revolutionize AI-Powered Biologics

Breakthrough Cardiometabolic Disease Treatments Valo Health and Novo Nordisk Expand Collaboration

Novo Nordisk and Valo Health Expand Partnership to Accelerate Cardiometabolic Disease Treatment Discovery Novo Nordisk A/S and Valo Health have announced a significant expansion of their collaboration aimed at discovering and developing innovative treatments for cardiometabolic diseases, including obesity, type…

Read MoreBreakthrough Cardiometabolic Disease Treatments Valo Health and Novo Nordisk Expand Collaboration

Groundbreaking Glucocorticoid Treatment in Congenital Adrenal Hyperplasia Neurocrine Biosciences Publishes Study $10 Million

Impact of High-Dose Glucocorticoid Therapy on Long-Term Health Neurocrine Biosciences has announced the publication of a comprehensive narrative review exploring the complexities of traditional glucocorticoid (GC) treatment for classic congenital adrenal hyperplasia (CAH) and the potential advantages of introducing novel…

Read MoreGroundbreaking Glucocorticoid Treatment in Congenital Adrenal Hyperplasia Neurocrine Biosciences Publishes Study $10 Million

Announces Breakthrough G-Rex® Grant: $125,000 Awarded to Seattle Children’s Therapeutics

Children’s Therapeutics ScaleReady Partners with Industry Leaders to Support Seattle Announces Children’s Therapeutics ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation, has announced that Seattle Children’s Therapeutics, a division of the prestigious Seattle Children’s Research Institute, has been…

Read MoreAnnounces Breakthrough G-Rex® Grant: $125,000 Awarded to Seattle Children’s Therapeutics

Bio-Techne Scores Major Victory in 2 Reverse Engineering Claim Against Miltenyi Biotec

Bio-Techne Prevails in Second Case Against Miltenyi Biotec for Reverse Engineering of Antibodies Corporation announced today that it has successfully won another legal claim against Miltenyi Biotec B.V. & Co. KG, which allegedly commercialized antibodies that were developed by reverse…

Read MoreBio-Techne Scores Major Victory in 2 Reverse Engineering Claim Against Miltenyi Biotec

Alzheimer’s Disease Breakthrough Unveiling the Mechanism Behind Lecanemab’s Role in Slowing Progression 2025

New Insights into Lecanemab’s Role in Slowing Alzheimer’s Disease Progression A groundbreaking study led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical, and Health Sciences at Kanazawa University, in collaboration with Eisai Co., Ltd., has uncovered a crucial…

Read MoreAlzheimer’s Disease Breakthrough Unveiling the Mechanism Behind Lecanemab’s Role in Slowing Progression 2025

Allergan Aesthetics Launches 3rd Annual CoolMonth: Exclusive Deals on CoolSculpting\u00ae Elite

CoolMonth Returns with Exciting Offers on CoolSculpting® Elite by Allergan Aesthetics Allergan Aesthetics, an AbbVie company has announced the return of its third annual CoolMonth celebration, showcasing CoolSculpting® Elite. This event offers a prime opportunity for individuals exploring non-surgical body…

Read MoreAllergan Aesthetics Launches 3rd Annual CoolMonth: Exclusive Deals on CoolSculpting\u00ae Elite

Cytokinetics Unveils Strategic 89,262 Inducement Grants in Compliance with Nasdaq Rule 5635(C)(4)

Cytokinetics, Incorporated has announced the granting of equity awards as material inducements to new employees under Nasdaq Listing Rule 5635(c)(4). These grants, made on December 31, 2024, include stock options, restricted stock units (RSUs), and performance stock units (PSUs) offered…

Read MoreCytokinetics Unveils Strategic 89,262 Inducement Grants in Compliance with Nasdaq Rule 5635(C)(4)

Genomics Growth in Precision Medicine Software Market 2024 4 Key Players Syapse, Fabric Genomics

The “Precision Medicine Software Market: Focused Insights 2024-2029” explores the dynamics Genomics of a rapidly growing industry. Valued at USD 1.72 billion in 2023, the market is expected to grow to USD 3.50 billion by 2029, reflecting a robust compound…

Read MoreGenomics Growth in Precision Medicine Software Market 2024 4 Key Players Syapse, Fabric Genomics

Chemotherapy-TEVIMBRA Approved in U.S. for 1st-line Treatment of Gastric Cancers

BeiGene a global oncology Chemotherapy company that plans to rebrand itself as BeOne Medicines Ltd., has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of TEVIMBRA® (tislelizumab-jsgr). This approval pertains to its use in combination…

Read MoreChemotherapy-TEVIMBRA Approved in U.S. for 1st-line Treatment of Gastric Cancers

Bristol Myers Squibb Announces Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis

Bristol Myers Squibb has announced positive results from arthritis two pivotal Phase 3 trials, POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), which evaluated the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met…

Read MoreBristol Myers Squibb Announces Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis